Clinical trialNCT05712187CompletedPhase 2Interventional

Phase 2b Study of ALTO-100 in MDD

SponsorAlto NeuroscienceEnrollment301Major Depressive Disorder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Adam Savitz, MD, PhD
Alto Neuroscience
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Site 174
Birmingham, Alabama, United States
Site 173
Huntsville, Alabama, United States
Site 136
Chandler, Arizona, United States
Site 139
Little Rock, Arkansas, United States
Site 141
Costa Mesa, California, United States
Site 118
Fresno, California, United States
Site 181
Imperial, California, United States
Site 182
Oceanside, California, United States
Site 188
Oceanside, California, United States
Site 179
Rancho Cucamonga, California, United States
Site 116
Sacramento, California, United States
Site 185
Centennial, Colorado, United States
Site 186
Brooksville, Florida, United States
Site 204
Jacksonville, Florida, United States
Site 205
Orlando, Florida, United States
Site 212
Tampa, Florida, United States
Site 213
Tampa, Florida, United States
Site 137
Carmel, Indiana, United States
Site 151
Baltimore, Maryland, United States
Site 108
Jackson, Mississippi, United States
Site 171
Jackson, Mississippi, United States
Site 142
Lincoln, Nebraska, United States
Site 144
Las Vegas, Nevada, United States
Site 178
Albuquerque, New Mexico, United States
Site 184
Brooklyn, New York, United States
Site 180
New York, New York, United States
Site 210
New York, New York, United States
Site 175
Westlake, Ohio, United States
Site 157
North Charleston, South Carolina, United States
Site 183
Memphis, Tennessee, United States
Site 147
Fort Worth, Texas, United States
Site 120
Houston, Texas, United States
Site 172
Houston, Texas, United States
Site 121
Draper, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ALTO-100Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Jan 2023
Primary completion: 5 Sept 2024
Completion: 24 Oct 2024
Last update posted: 8 Sept 2025
Registered enrollment: 301
Registry id: NCT05712187

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.